	US 11,896,645 B2
	Compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions
Stefan Franz Thomas Weiss, Johannesburg (ZA); Boitelo Theresiah Letsolo, Johannesburg (ZA); Kerrilyn Naidoo, Durban (ZA); and Tyrone Chad Otgaar, Roodepoort (ZA)
Assigned to UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG, Johannesburg (ZA)
Filed by UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG, Johannesburg (ZA)
Filed on Feb. 17, 2021, as Appl. No. 17/177,614.
Application 17/177,614 is a division of application No. 15/773,453, abandoned, previously published as PCT/IB2016/056686, filed on Nov. 7, 2016.
Claims priority of application No. 1519557 (GB), filed on Nov. 5, 2015.
Prior Publication US 2021/0169974 A1, Jun. 10, 2021
Int. Cl. A61K 38/17 (2006.01); C12N 15/113 (2010.01); C07K 14/705 (2006.01); A61P 17/06 (2006.01); A61P 21/00 (2006.01); A61P 9/10 (2006.01); A61P 39/00 (2006.01); A61P 3/10 (2006.01); A61P 35/04 (2006.01); A61P 19/10 (2006.01); A61K 39/395 (2006.01); C07K 16/28 (2006.01)

CPC A61K 38/177 (2013.01) [A61K 39/395 (2013.01); A61P 3/10 (2018.01); A61P 9/10 (2018.01); A61P 17/06 (2018.01); A61P 19/10 (2018.01); A61P 21/00 (2018.01); A61P 35/04 (2018.01); A61P 39/00 (2018.01); C07K 14/70546 (2013.01); C07K 16/28 (2013.01); C12N 15/113 (2013.01); C12N 2310/14 (2013.01)]

6 Claims

1. A method comprising: (a) transfecting a cell with a transfecting agent and (b) producing within the cell a 37 kDa/67 kDa laminin receptor precursor/high affinity laminin receptor (LRP/LR) comprising the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2; wherein the level of human telomerase reverse transcription, telomerase activity, and/or telomere length is increased; and wherein the level of a senescent marker is decreased.